GO
| HSI1 | 26,085.08 | +149.18 | 210.47B |
| HSCEI1 | 9,198.30 | +91.82 | 89.02B |
| Back Zoom + Zoom - Block Traded | |
|
2025-12-05 10:04:06 GIANT BIOGENE (02367.HK) updated its full-year results guidance and addressed major risks to 2025 earnings during a conference call on December 2, according to a report from HSBC Global Research. Due to growth pressures on the Comfy brand, the broker lowered its 2025-27 earnings forecasts for GIANT BIOGENE by 17-25%, yet the medical beauty business may serve as a positive catalyst in 2026. GIANT BIOGENE's rating was kept as Buy, but its target price was reduced from HKD69.3 to HKD46.4 because of the downward revision of earnings expectations. ~ AAStocks Financial News Web Site: www.aastocks.com | |